Comparative Pharmacology
Head-to-head clinical analysis: TRIPTODUR KIT versus VIADUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIPTODUR KIT versus VIADUR.
TRIPTODUR KIT vs VIADUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist; continuous administration suppresses pituitary gonadotropin (LH and FSH) secretion, leading to decreased testosterone production in males and estrogen production in females.
Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist that stimulates pituitary gonadotropin release initially, followed by sustained suppression of pituitary gonadotropins due to receptor desensitization, leading to reduced testosterone production.
3.75 mg intramuscularly once every 28 days.
Leuprolide acetate implant 65 mg implanted subcutaneously in the inner aspect of the upper arm once yearly.
None Documented
None Documented
Terminal elimination half-life is 28-35 hours in healthy adults, allowing for a 4-week dosing interval. In patients with renal impairment, half-life is prolonged.
The terminal elimination half-life of leuprolide acetate following subcutaneous administration is approximately 3 hours. In patients with renal impairment, half-life may be prolonged; however, no dose adjustment is recommended for mild-to-moderate impairment.
Renal (approximately 50% as unchanged drug and metabolites); biliary/fecal (approximately 20-30%); the remainder is metabolized.
Leuprolide acetate is primarily eliminated via hepatic metabolism and renal excretion. Approximately 48% of the dose is recovered in urine over 24 hours, with 5% as unchanged drug. Fecal excretion accounts for about 5%.
Category C
Category C
GnRH Agonist
GnRH Agonist